Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats.
A group of 3-month-old Sprague-Dawley rats were sham operated or ovariectomized and given daily injections of human PTH-(1-34) (8 or 16 micrograms per 100 g body weight) for 5 weeks. At the termination of the study histomorphometric techniques were used to examine changes in cortical and cancellous bone in the diaphysis and proximal metaphysis of the tibia. Ovariectomy resulted in a 50% decrease in cancellous bone that was accompanied by a 41 and 120% increase in osteoclasts and osteoblasts, respectively. In contrast, in the ovariectomized animals treated with PTH, the metaphyseal cancellous bone increased by over 300% to a level in excess of that present in the sham-operated control animals. The increase in cancellous bone induced by PTH was associated with an over 70% increase in osteoblasts and tetracycline-labeled area and an unexpected decrease in trabecular osteoclasts. In the tibial diaphysis PTH also decreased endosteal osteoclasts and at the same time increased osteoblast size and number as well as endosteal and periosteal bone formation; ovariectomy increased only periosteal bone formation. Our findings demonstrate that intermittent administration of PTH prevents ovariectomy-induced bone loss and augments cancellous and cortical bone formation in sexually mature ovariectomized rats. Although the basis of the bone anabolic action of PTH remains elusive, our data indicate that it may involve the uncoupling of bone formation and resorption such that the latter is inhibited as bone formation is enhanced. Our findings are also compatible with the view that intermittent administration of PTH increases bone mass, in part by stimulating the proliferation and differentiation of osteoblast progenitors while inhibiting osteoclast proliferation.
Liu
C C
CC
Research Service, American Lake Veterans Administration Medical Center, Tacoma, WA 98493.
Kalu
D N
DN
D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000473:pathology; D010024:Osteoporosis / Q000517:prevention & control*; D010052:Ovariectomy; D010053:Ovary / Q000502:physiology*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D010521:Periosteum / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains; D012741:Sexual Maturation / Q000502:physiology*; D019379:Teriparatide; D013977:Tibia / Q000473:pathology
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D019379:Teriparatide